BACKGROUND: Sclerostin alters bone formation. The precise and reproducible measurement of sclerostin concentrations in biological samples is important for assessment of metabolic bone disease. We determined sclerostin concentrations in serum and plasma using two commercially available ELISA. METHODS: We measured sclerostin concentrations in serum or heparin-plasma obtained from 25 normal human subjects using two commercial ELISA available from Biomedica Medizinprodukte GmbH and TECOmedical AG. RESULTS: With the Biomedica assay, serum sclerostin concentrations were 0.99 ± 0.12 ng/ml (mean ± sem), and plasma concentrations were 1.47 ± 0.13 ng/ml (paired t test, P < 0.001). With the TECO assay, serum sclerostin levels were 0.71 ± 0.05 ng/ml, and plasma sclerostin concentrations were 0.80 ± 0.06 ng/ml (paired t test, P < 0.001). Serum and plasma sclerostin concentrations were significantly different when determined by the two assays (serum, P = 0.015; plasma, P < 0.001). Recovery of added recombinant sclerostin to serum was less than expected with both Biomedica and TECO assays (P < 0.001, paired t test). CONCLUSIONS: The concentrations of sclerostin in serum and plasma are different when determined by the two assays. Serum or plasma sclerostin concentrations with current assays should be interpreted with caution. The data suggest that the same assay should be used for comparing groups of patients or patients being followed longitudinally. Standardization of sclerostin assays is required before being introduced into general clinical laboratory use.
BACKGROUND:Sclerostin alters bone formation. The precise and reproducible measurement of sclerostin concentrations in biological samples is important for assessment of metabolic bone disease. We determined sclerostin concentrations in serum and plasma using two commercially available ELISA. METHODS: We measured sclerostin concentrations in serum or heparin-plasma obtained from 25 normal human subjects using two commercial ELISA available from Biomedica Medizinprodukte GmbH and TECOmedical AG. RESULTS: With the Biomedica assay, serum sclerostin concentrations were 0.99 ± 0.12 ng/ml (mean ± sem), and plasma concentrations were 1.47 ± 0.13 ng/ml (paired t test, P < 0.001). With the TECO assay, serum sclerostin levels were 0.71 ± 0.05 ng/ml, and plasma sclerostin concentrations were 0.80 ± 0.06 ng/ml (paired t test, P < 0.001). Serum and plasma sclerostin concentrations were significantly different when determined by the two assays (serum, P = 0.015; plasma, P < 0.001). Recovery of added recombinant sclerostin to serum was less than expected with both Biomedica and TECO assays (P < 0.001, paired t test). CONCLUSIONS: The concentrations of sclerostin in serum and plasma are different when determined by the two assays. Serum or plasma sclerostin concentrations with current assays should be interpreted with caution. The data suggest that the same assay should be used for comparing groups of patients or patients being followed longitudinally. Standardization of sclerostin assays is required before being introduced into general clinical laboratory use.
Authors: David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham Journal: EMBO J Date: 2003-12-01 Impact factor: 11.598
Authors: W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul Journal: Hum Mol Genet Date: 2001-03-01 Impact factor: 6.150
Authors: Kenneth E S Poole; Rutger L van Bezooijen; Nigel Loveridge; Herman Hamersma; Socrates E Papapoulos; Clemens W Löwik; Jonathan Reeve Journal: FASEB J Date: 2005-08-25 Impact factor: 5.191
Authors: Peter ten Dijke; Carola Krause; David J J de Gorter; Clemens W G M Löwik; Rutger L van Bezooijen Journal: J Bone Joint Surg Am Date: 2008-02 Impact factor: 5.284
Authors: David G Winkler; Changpu Yu; James C Geoghegan; Ethan W Ojala; John E Skonier; Diana Shpektor; May K Sutherland; John A Latham Journal: J Biol Chem Date: 2004-06-14 Impact factor: 5.157
Authors: May Kung Sutherland; James C Geoghegan; Changpu Yu; Eileen Turcott; John E Skonier; David G Winkler; John A Latham Journal: Bone Date: 2004-10 Impact factor: 4.398
Authors: David G Winkler; May S Kung Sutherland; Ethan Ojala; Eileen Turcott; James C Geoghegan; Diana Shpektor; John E Skonier; Changpu Yu; John A Latham Journal: J Biol Chem Date: 2004-11-12 Impact factor: 5.157
Authors: Alexander T Faje; Pouneh K Fazeli; Debra K Katzman; Karen K Miller; Anne Breggia; Clifford J Rosen; Nara Mendes; Anne Klibanski; Madhusmita Misra Journal: Bone Date: 2012-06-15 Impact factor: 4.398
Authors: Yu-Heng Vivian Ma; Ann V Schwartz; Sigurdur Sigurdsson; Trisha F Hue; Thomas F Lang; Tamara B Harris; Clifford J Rosen; Eric Vittinghoff; Gudny Eiriksdottir; Alda M Hauksdottir; Kristin Siggeirsdottir; Gunnar Sigurdsson; Diana Oskarsdottir; Nicola Napoli; Lisa Palermo; Vilmundur Gudnason; Xiaojuan Li Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958
Authors: Matthew T Drake; Jennifer S Fenske; Frank A Blocki; Claudia Zierold; Natasha Appelman-Dijkstra; Socrates Papapoulos; Sundeep Khosla Journal: Bone Date: 2018-03-14 Impact factor: 4.398
Authors: Gina N Woods; Susan K Ewing; Sigurdur Sigurdsson; Deborah M Kado; Joachim H Ix; Trisha F Hue; Gudny Eiriksdottir; Kaipin Xu; Vilmundur Gudnason; Thomas F Lang; Eric Vittinghoff; Tamara B Harris; Clifford J Rosen; Xiaojuan Li; Ann V Schwartz Journal: J Bone Miner Res Date: 2018-08-27 Impact factor: 6.741
Authors: A H van Lierop; A W van der Eerden; N A T Hamdy; A R Hermus; M den Heijer; S E Papapoulos Journal: J Clin Endocrinol Metab Date: 2012-07-27 Impact factor: 5.958